Abstract 165P
Background
Sorafenib has been the standard-of-care in advanced hepatocellular carcinoma (HCC). Prognostic factors such as BCLC stage and macroscopic vascular invasion (MVI), together with predictive factors of response such as neutrophil-lymphocyte ratio (NLR), cirrhosis etiology and extrahepatic spread (EHS) were found to be associated to survival outcomes. Nevertheless, these factors need to be fully validated. We intend to explore and identify prognostic factors for overall survival (OS) in a European population sample treated with sorafenib.
Methods
Multicentre retrospective evaluation of patients’ (pts) charts of HCC pts with ECOG performance status (PS) ≤2 treated with sorafenib between 2008 and 2019 in two Portuguese centres. Alfa- fetoprotein (AFP) < 200 ng/mL, EHS, Model for End-Stage Liver Disease-Na (MELD-Na) < 17, cutaneous toxicity, NLR < 2.3, MVI and previous locoregional treatment (LRT) were considered for stratification. Each factor was analyzed by Kaplan-Meier method for OS estimation and a multivariate Cox regression was performed.
Results
Eighty-six pts were analyzed, 15% female and with a median age (med) of 65.5 years [36-83]. Considering underlying cause, 45% pts had alcohol-related liver disease, 23% hepatitis C virus, 14% hepatitis B virus and 5% non-alcoholic steatosis hepatitis. Median OS was 8.5 months (m). Kaplan-Meier analysis of OS proved to be statistical significant in the following factors: AFP < 200 ng/mL med OS 12.5 m and ≥ 200 ng/mL 5.4 m (p < 0.0001); MELD-Na < 17 med OS 10.4 m and ≥ 17 4.8 m (p=0.015); absence of EHS med OS 10.0 m and presence of EHS med OS 7.3 m (p=0.028); previous LRT med OS 11.2 m and no LRT med OS 6.6 m (p=0.005). Multivariate Cox analysis identified extra-hepatic involvement (HR 1.002, p=0.041) and no previous LRT (HR 1.871, p=0.009) as risk factors.
Conclusions
HCC pts represent a heterogeneous population with many factors that potentially affect prognosis, such as geographic etiology difference in hepatic cirrhosis. In our sample, analysis of single-variable subgroups estimated greater OS in pts with AFP < 200 ng/mL, MELD-Na < 17, absence of EHS and previous LRT. The multivariate regression showed EHS and no previous LRT are independent factors for worse prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session